Sep 18, 2013, 02.39 PM | Source: CNBC-TV18
Manoj Murlidharan Vayalar of IIFL recommends selling Sun Pharmaceutical Industries with a target of Rs 520 and a stoploss at Rs 555.
Manoj Murlidharan (more)
Head- Derivatives, Religare Securities | Capital Expertise: F&O
At 14:12 hrs Sun Pharmaceutical Industries was quoting at Rs 544.55, up Rs 0.20, or 0.04 percent. It has touched an intraday high of Rs 550 and an intraday low of Rs 535.55.
The share touched its 52-week high Rs 583 and 52-week low Rs 344.73 on 16 September, 2013 and 15 November, 2012, respectively. Currently, it is trading 6.6 percent below its 52-week high and 57.96 percent above its 52-week low. Market capitalisation stands at Rs 112,785.23 crore.
Disclosure: We have discussed this with our clients but no personal holdings.
Stay invested in Sun Pharma, says Ashish Kyal
Ashish Kyal of wavesstrategy.com is of the view th
Sun Pharma Advanced Research's Q3 net loss widens to Rs 41 cr
The company had posted a net loss of Rs 18.91 cror
Sun Pharma gains; launches Imatinib Mesylate in US market
The company's subsidiary has received final approv
Sun hopes cut-price generic Gleevec will win third of US market
Gleevec, or imatinib mesylate, costs up to about U
Sun completes sale of 2 Ranbaxy divisions to Strides
Sun Pharma may test Rs 885-900, says Yogesh Mehta
Yogesh Mehta of Motilal Oswal Securities is of the
Prefer pharma, Alembic Pharma looks interesting: Dipan Mehta
Dipan Mehta, Member at BSE & NSE is of the view th
Sell Bosch, Jubilant Food; buy Bata India: CA Rudramurthy BV
CA Rudramurthy BV of Vachana Investments recommend